| Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. | |
| | |
MedLine Citation:
|
PMID: 7926977 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND. Tumor necrosis factor (TNF) and interleukin-1 beta (IL-1) are two cytokines with erythropoietic inhibitory activity which may be involved in the pathogenesis of some types of anemia that may respond to recombinant erythropoietin (r-EPO). The aim of the present study was to evaluate whether TNF and IL-1 serum levels are related to clinical response in patients with myelodysplastic syndromes (MDS) receiving r-EPO. TNF and IL-1 serum levels were measured by means of immunoenzymatic assays in 26 patients affected by MDS and treated with r-EPO administered subcutaneously at dosages up to 1050 U/kg a week, for at least two months. Four patients (15%) showed a significant response, with an increase of hemoglobin > 2 g/dL and complete suspension of transfusions. Higher mean serum levels of both TNF (54.2 +/- 93 vs 4.2 +/- 7.9 pg/mL, p < 0.001) and IL-1 (114 +/- 58.5 vs 36.1 +/- 21.7 pg/mL, p < 0.001) were measured in MDS patients than in a group of 42 normal controls. However, responders showed significantly lower mean levels of TNF (8.2 +/- 9.6 vs 58.5 +/- 65.2 pg/mL, p < 0.05) and IL-1 (30 +/- 24.8 vs 127.8 +/- 51.4 pg/mL, p < 0.001) than those of non responders. In terms of absolute values, all responders evidenced undetectable or normal levels of both cytokines. No relationship was found between TNF or IL-1 and values of hemoglobin, serum erythropoietin, ferritin, soluble transferrin receptor or transfusional requirements. MDS patients who respond to r-EPO have lower serum levels of TNF and IL-1 than those who do not respond. |
| | |
Authors:
|
P Musto; R Matera; M M Minervini; C Checchia-de Ambrosio; C Bodenizza; A Falcone; M Carotenuto |
Related Documents
:
|
15189947 - Serum levels of the apoptosis-associated molecules, tumor necrosis factor-alpha/tumor n... 17452737 - Cytokines and c-reactive protein production in hip-fracture-operated elderly patients. 18577187 - High-sensitivity c-reactive protein measurements in patients with non-arteritic anterio... 10824887 - Role of serum c-reactive protein as a marker of hepatocellular carcinoma in patients wi... 23542317 - Correlation of brain biomarker neuron specific enolase (nse) with degree of disability ... 12800377 - Hepatic hemangioendothelioma in children: analysis of thirteen cases. |
Publication Detail:
|
Type: Clinical Trial; Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Haematologica Volume: 79 ISSN: 0390-6078 ISO Abbreviation: Haematologica Publication Date: 1994 May-Jun |
Date Detail:
|
Created Date: 1994-11-10 Completed Date: 1994-11-10 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 0417435 Medline TA: Haematologica Country: ITALY |
Other Details:
|
Languages: eng Pagination: 265-8 Citation Subset: IM |
Affiliation:
|
Division of Hematology, IRCCS Casa Sollievo della Sofferenza Hospital, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Erythropoietin / therapeutic use* Humans Interleukin-1 / blood* Middle Aged Myelodysplastic Syndromes / blood*, drug therapy* Recombinant Proteins / therapeutic use Treatment Outcome Tumor Necrosis Factor-alpha / metabolism* |
| Chemical | |
Reg. No./Substance:
|
0/Interleukin-1; 0/Recombinant Proteins; 0/Tumor Necrosis Factor-alpha; 11096-26-7/Erythropoietin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Multiple myeloma associated with autoimmune hemolytic anemia.
Next Document: Flow cytometric analysis of anti-platelet antibodies in idiopathic thrombocytopenic purpura.